Boston Scientific's MedSurg Diversification Bolsters Growth Prospects
Article excerpt
Highlighted: the sentence this signal was extracted from
Boston Scientific 's BSX MedSurg segment continues to provide a diversified and stable revenue base. Within this, Endoscopy sales grew 7% year over year in the second quarter of 2026, driven by strong performance across the business and another better-than-expected quarter for AXIOS Stent and Delivery System. The company also received FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges and simplify endoscopic ultrasound biliary drainage. Urology results fell short of its expectations, growing 1% this quarter, as the recovery in sacral neuromodulation continued to take longer than anticipated. Stone management also remained under pressure due to key portfolio gaps that the company plans to address over the next three quarters. Management now expects full-year growth in the business to be flat to low-single digits. However, Boston Scientific remains confident that the long-term trajectory in Urology will improve in 2027. Three key launches are planned for its core stone portfolio over the next two to three quarters, which should help the business move closer to market growth next year. The company has also addressed a significant disruption to its sacral neuromodulation commercial capabilities by hiring and training new clinical and sales representatives, who are now in the field. Neuromodulation sales grew 12% in the second...
Keep reading with a free account
The rest of this article, and every signal for Boston Scientific, is in your free account.
